Differential efficacy of biologic treatments targeting the TNF-α/IL-23/IL-17 axis in psoriasis and psoriatic arthritis

Kazuhisa Furue; Takamichi Ito; Masutaka Furue

doi:10.1016/j.cyto.2018.08.025

Differential efficacy of biologic treatments targeting the TNF-α/IL-23/IL-17 axis in psoriasis and psoriatic arthritis

Kazuhisa Furue, Takamichi Ito, Masutaka Furue

研究成果: Contribution to journal › Review article › 査読

21 被引用数 (Scopus)

抄録

Psoriasis and psoriatic arthritis cause significant physical and psychological burdens for afflicted individuals. An accelerated TNF-α/IL-23/IL-17 axis is their major pathomechanism; therefore, anti-TNF-α/IL-23/IL-17 biologics are very effective for the treatment of skin and joint lesions in psoriasis and psoriatic arthritis. Given that the IL-17 signature is more upregulated in the skin than in synovium in psoriatic arthritis, anti-IL-23/IL-17 agents seem to be superior to anti-TNF-α remedies in the treatment of skin lesions. In this review, we focus on the differential efficacy of anti-TNF-α/IL-23/IL-17 biologics in psoriasis and psoriatic arthritis.

本文言語	英語
ページ（範囲）	182-188
ページ数	7
ジャーナル	Cytokine
巻	111
DOI	https://doi.org/10.1016/j.cyto.2018.08.025
出版ステータス	出版済み - 11 2018

All Science Journal Classification (ASJC) codes

Immunology and Allergy
Immunology
Biochemistry
Hematology
Molecular Biology

文献へのアクセス

10.1016/j.cyto.2018.08.025

フィンガープリント「Differential efficacy of biologic treatments targeting the TNF-α/IL-23/IL-17 axis in psoriasis and psoriatic arthritis」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル

@article{f0559552d3594723be02fdf517f3f7df,

title = "Differential efficacy of biologic treatments targeting the TNF-α/IL-23/IL-17 axis in psoriasis and psoriatic arthritis",

abstract = "Psoriasis and psoriatic arthritis cause significant physical and psychological burdens for afflicted individuals. An accelerated TNF-α/IL-23/IL-17 axis is their major pathomechanism; therefore, anti-TNF-α/IL-23/IL-17 biologics are very effective for the treatment of skin and joint lesions in psoriasis and psoriatic arthritis. Given that the IL-17 signature is more upregulated in the skin than in synovium in psoriatic arthritis, anti-IL-23/IL-17 agents seem to be superior to anti-TNF-α remedies in the treatment of skin lesions. In this review, we focus on the differential efficacy of anti-TNF-α/IL-23/IL-17 biologics in psoriasis and psoriatic arthritis.",

author = "Kazuhisa Furue and Takamichi Ito and Masutaka Furue",

year = "2018",

month = nov,

doi = "10.1016/j.cyto.2018.08.025",

language = "English",

volume = "111",

pages = "182--188",

journal = "Cytokine",

issn = "1043-4666",

publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Differential efficacy of biologic treatments targeting the TNF-α/IL-23/IL-17 axis in psoriasis and psoriatic arthritis

AU - Furue, Kazuhisa

AU - Ito, Takamichi

AU - Furue, Masutaka

PY - 2018/11

Y1 - 2018/11

N2 - Psoriasis and psoriatic arthritis cause significant physical and psychological burdens for afflicted individuals. An accelerated TNF-α/IL-23/IL-17 axis is their major pathomechanism; therefore, anti-TNF-α/IL-23/IL-17 biologics are very effective for the treatment of skin and joint lesions in psoriasis and psoriatic arthritis. Given that the IL-17 signature is more upregulated in the skin than in synovium in psoriatic arthritis, anti-IL-23/IL-17 agents seem to be superior to anti-TNF-α remedies in the treatment of skin lesions. In this review, we focus on the differential efficacy of anti-TNF-α/IL-23/IL-17 biologics in psoriasis and psoriatic arthritis.

AB - Psoriasis and psoriatic arthritis cause significant physical and psychological burdens for afflicted individuals. An accelerated TNF-α/IL-23/IL-17 axis is their major pathomechanism; therefore, anti-TNF-α/IL-23/IL-17 biologics are very effective for the treatment of skin and joint lesions in psoriasis and psoriatic arthritis. Given that the IL-17 signature is more upregulated in the skin than in synovium in psoriatic arthritis, anti-IL-23/IL-17 agents seem to be superior to anti-TNF-α remedies in the treatment of skin lesions. In this review, we focus on the differential efficacy of anti-TNF-α/IL-23/IL-17 biologics in psoriasis and psoriatic arthritis.

UR - http://www.scopus.com/inward/record.url?scp=85052470976&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052470976&partnerID=8YFLogxK

U2 - 10.1016/j.cyto.2018.08.025

DO - 10.1016/j.cyto.2018.08.025

M3 - Review article

C2 - 30172115

AN - SCOPUS:85052470976

VL - 111

SP - 182

EP - 188

JO - Cytokine

JF - Cytokine

SN - 1043-4666

ER -